A novel targeted immunotherapy for CTCL is on its way: Anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies

Cutaneous T-cell lymphomas (CTCLs) represent a group of rarely occurring and clinically and pathologically heterogeneous diseases that are considered incurable at advanced stages. Current treatments provide limited clinical benefit and are thus largely amenable to improvement. An antibody-based CTCL...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncoimmunology
Autors principals: Sicard, Hélène, Bonnafous, Cécile, Morel, Ariane, Bagot, Martine, Bensussan, Armand, Marie-Cardine, Anne
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2015
Matèries:
Author's View
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4570095/
https://ncbi.nlm.nih.gov/pubmed/26405593
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1022306
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars